Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
According to MarketBeat, Cellectis has a consensus rating of Moderate Buy and a consensus price target of $10.
Bpifrance SA acquired a new position in shares of Cellectis in the first quarter valued at approximately $4,221,000.
Cellectis has been utilizing gene editing technology for 23 years, and specifically focuses TALEN on for electroporation.
Source: https://investorplace.com/2023/01/7-crispr-stocks-with-the-best-long-term-potential/